The US FDA has cleared the first updates to the algorithm of the Omnipod 5 automated insulin delivery (AID) system (Insulet ...

Medtrum today unveiled the 300-unit version of its TouchCare Nano tubeless automated insulin delivery patch pump.

Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) ...

Insulet anticipates that the Omnipod 5 algorithm update will launch in the US in H1 2026. The company highlighted that the ...

Growth stocks reflect firms on track for swift expansion, beating peers and the overall market. Their strategy to reinvest ...

December 4, 2025 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the ...

Torrey Pines High School. I’ve been living with Type 1 diabetes for over five years, and this weekend, I’ll be attending the ...

PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further validate the test's ability to assess risk ...

Submission delayed by U.S. government shutdown; initial FDA questions expected during Q4 2025 "The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch ...

Around 830 million people globally are living with diabetes, as per WHO. This is a stark reminder that the global diabetes crisis is more serious than ever. For many of us, diabetes immediately brings ...

Insulet’s stock price target has recently been raised, with the fair value estimate increasing from $366 to $378 following the company's Investor Day and updated outlook. This change reflects ...